Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis

Kidney International

Volumn 86, Issue 1, 2014, Pages 75-85

  Chow, Bryna S Man ^a,b   Kocan, Martina ^c   Bosnyak, Sanja ^c   Sarwar, Mohsin ^c   Wigg, Belinda ^d   Jones, Emma S ^c   Widdop, Robert E ^c   Summers, Roger J ^c   Bathgate, Ross A D ^a,b   Hewitson, Tim D ^b,d   Samuel, Chrishan S ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

AT2 receptor; fibrosis; kidney disease; relaxin; Smad2; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 2 RECEPTOR; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; COLLAGENASE 3; GELATINASE A; GELATINASE B; HETERODIMER; HORMONE RECEPTOR; HUMAN GENE 2 RELAXIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NEURONAL NITRIC OXIDE SYNTHASE; RECOMBINANT RELAXIN; RELAXIN FAMILY PEPTIDE RECEPTOR 1; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; LGR7 PROTEIN, MOUSE; LGR7 PROTEIN, RAT; PYRIDINE DERIVATIVE; RECEPTOR; RECOMBINANT PROTEIN; RELAXIN; RLN2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG EFFECT; DRUG RECEPTOR BINDING; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HORMONE ACTION; HORMONE BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; RENAL INTERSTITIAL FIBROSIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PROTEIN MULTIMERIZATION; RENAL INSUFFICIENCY, CHRONIC; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; CELLS, CULTURED; DISEASE PROGRESSION; FIBROSIS; HUMANS; IMIDAZOLES; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MYOFIBROBLASTS; PROTEIN MULTIMERIZATION; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RECOMBINANT PROTEINS; RELAXIN; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84903773477     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.518     Document Type: Article

References (51)

1. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365. (Pubitemid 41376493)
2. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
3. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508. (Pubitemid 27469555)
4. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
5. Stahl PJ, Felsen D. Transforming growth factor-b, basement membrane, and epithelial-mesenchymal transdifferentiation. Am J Pathol 2001; 159: 1187-1192.
6. Bathgate RAD, Hsueh AJ, Sherwood OD. Physiology and molecular biology of the relaxin peptide family. In: Neill JD (eds). Knobil and Neills Physiology of Reproduction, 3rd edn Raven Press: New York, NY, 2006, pp 679-770.
7. Samuel CS, Hewitson TD, Unemori EN et al. Drugs of the future: The hormone relaxin. Cell Mol Life Sci 2007; 64: 1539-1557. (Pubitemid 46954152)
8. Samuel CS, Hewitson TD. Relaxin and the progression of kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 9-14.
9. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Transl Res 2009; 154: 1-6.
10. Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
11. Heeg MH, Koziolek MJ, Vasko R et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005; 68: 96-109. (Pubitemid 43181367)
12. Mookerjee I, Hewitson TD, Halls ML et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 2009; 23: 1219-1229.
13. Chow BS, Chew EG, Zhao C et al. Relaxin signals through a RXFP1-pERKnNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: The additional involvement of iNOS. PLoS One 2012; 7: E42714.
14. Li JH, Zhu HJ, Huang XR et al. Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464-1472. (Pubitemid 34579235)
15. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 1999; 21: 658-665. (Pubitemid 129502284)
16. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990; 265: 106981-110685.
17. Unemori EN, Pickford LB, Salles AL et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-2745. (Pubitemid 26427400)
18. Bennett RG, Kharbanda KK, Tuma DJ. Inhibition of markers of hepatic stellate cell activation by the hormone relaxin. Biochem Pharmacol 2003; 66: 867-874. (Pubitemid 37011425)
19. Samuel CS, Unemori EN, Mookerjee I et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145: 4125-4133. (Pubitemid 39120561)
20. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-188.
21. Ruster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011; 22: 1189-1199.
22. Jones ES, Vinh A, McCarthy CA et al. AT2 receptors: Functional relevance in cardiovascular disease. Pharm Ther 2008; 120: 292-316.
23. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor. Hypertension 2005; 45: 840-844.
24. Van der Westhuizen ET, Werry TD, Sexton PM et al. The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. Mol Pharmacol 2007; 71: 1618-1629. (Pubitemid 47010915)
25. Halls ML, Bathgate RA, Summers RJ. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol Pharmacol 2006; 70: 214-226.
26. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264-269. (Pubitemid 27349072)
27. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182-1191. (Pubitemid 29006033)
28. Nie W, Yan H, Li S et al. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Mol Immunol 2009; 46: 335-361.
29. Savoia C, Ebrahimian T, He Y et al. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 2006; 24: 2417-2422. (Pubitemid 44684690)
30. Yang J, Chen C, Ren H et al. Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens 2012; 30: 1176-1184.
31. Nakajima M, Hutchinson HG, Fujinaga M et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gainof-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663-10667.
32. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not No-nitro-L-Arginine methyl ester hypertensive rats. Hypertension 2011; 58: 197-204.
33. Szabo AJ, Wagner L, Erdely A et al. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003; 64: 1765-1771. (Pubitemid 37323705)
34. Ma J, Nishimura H, Fogo A et al. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998; 53: 937-944. (Pubitemid 28155667)
35. Svendsen AM, Zalesko A, K-nig J et al. Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1. Mol Cell Endocrinol 2008; 296: 10-17.
36. Siddiquee K, Hampton J, McAnally D et al. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 2013; 168: 1104-1117.
37. Hewitson TD, Ho WY, Samuel CS. Anti-fibrotic properties of relaxin: In vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 2010; 151: 4938-4948.
38. Diamond JR, Ricardo SD, Klahr S. Mechanisms of interstitial fibrosis in obstructive nephropathy. Semin Nephrol 1998; 18: 594-602. (Pubitemid 28506731)
39. Hein L, Barsh GS, Pratt RE et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-777.
40. Rodemann HP, Muller GA. Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol Med 1990; 195: 57-63. (Pubitemid 20337244)
41. Masterson R, Hewitson TD, Kelynack K et al. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 2004; 19: 544-552. (Pubitemid 38263111)
42. Samuel CS, Zhao C, Bathgate RA et al. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003; 17: 121-123.
43. Gemici B, Tan R, Ongüt G et al. Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemia-reperfusion: Role of angiotensin II. J Surg Res 2010; 161: 126-133.
44. Gallop PM, Paz MA. Posttranslational protein modifications, with special attention to collagen and elastin. Physiol Rev 1975; 55: 418-487.
45. Kocan M, See HB, Seeber RM et al. Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J Biomol Screen 2008; 13: 888-898.
46. Kocan M, See HB, Sampaio NG et al. Agonist-independent interactions between beta-Arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol Endocrinol 2009; 23: 559-571.
47. Kocan M, Dalrymple MB, Seeber RM et al. Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and beta-Arrestins. Front Endocrinol (Lausanne) 2010; 1: 12.
48. Mercier JF, Salahpour A, Angers S et al. Quantitative assessment of beta 1-And beta 2-Adrenergic receptor homo-And heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 2002; 277: 44925-44931. (Pubitemid 36159089)
49. D'amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005; 46: 1347-1354.
50. Thomas WG, Motel TJ, Kule CE et al. Phosphorylation of the angiotensin II (AT(1A)) receptor carboxyl terminus: A role in receptor endocytosis. Mol Endocrinol 1998; 12: 1513-1524. (Pubitemid 30663434)
51. Bosnyak S, Jones ES, Christopoulos A et al. Relative affinity of angiotensin peptides and novel ligands at AT(1) and AT(2) receptors. Clin Sci 2011; 121: 297-303.